Swissmedic extends MenQuadfi indication in Switzerland to 6 weeks; expands protection to youngest infants
Swissmedic extends MenQuadfi indication in Switzerland to 6 weeks; expands protection to youngest infants MenQuadfi® (active substance: polysaccharides of Neisseria meningitidis groups A, C, W-135 and Y conjugated to tetanus toxoid carrier protein) Solution for injection for active immunisation against invasive meningococcal disease in children from 6 weeks of age and adults The active substance in the vaccine MenQuadfi comprises polysaccharides of Neisseria meningitidis groups A, C, W-135 and Y which are bound to the tetanus toxoid carrier protein. MenQuadfi is available as a ready-to-use solution for injection in single doses. ...